Search

Your search keyword '"Melero, Ignacio"' showing total 1,566 results

Search Constraints

Start Over You searched for: Author "Melero, Ignacio" Remove constraint Author: "Melero, Ignacio"
1,566 results on '"Melero, Ignacio"'

Search Results

52. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis

53. 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

55. Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies

57. Contributors

64. Cytokines in clinical cancer immunotherapy

65. Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011

66. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

67. Defining the Critical Hurdles in Cancer Immunotherapy

68. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

71. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

73. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming.

76. A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

77. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

78. Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

79. Supplementary Data from Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

80. Supplementary Figure from A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β

82. Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

83. Data from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

84. Data from Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

85. Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

86. Abstract 614: CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

87. Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

88. Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

89. Data from A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β

90. Supplementary Data from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

91. Supplementary Figure from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

92. Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

93. Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

94. Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes

95. Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes

96. Supplementary Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

97. Supplementary Figure 2 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

98. Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

99. Supplementary figure 3 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies

Catalog

Books, media, physical & digital resources